retatrutide weight loss retatrutide clinical trial Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a Retatrutide, an experimental weight-loss drug,

Purpose-built for physicians GLP-1s show clear signal of reduced rheumatoid arthritis, gout, osteoarthritis risks Key takeaways: Use of GLP-1 receptor agonists in diabetes was associated with reduced risk for RA and gout

A retatrutide starting dose, a dose-escalation step, and a maintenance dose describe different parts of a plan

Louis, United States Updates Copyright 2023 Mazzieri, Basta, Calafiore and Luca

Summary: GLP-1/GIP medicines (such as semaglutide and tirzepatide) are diabetes and weight management treatments that may indirectly affect vitamin B12 levels through altered gastric function, reduced dietary intake, and interaction with concurrent metformin use

GIP receptor activation becomes more significant at the 4mg dose level and continues to increase through the dose range

As always, discuss with your care team, and of course, remember that small tweaks lead to massive peaks